CHIMERIC THERAPEUTICS LIMITED — Director's Dealing 2022

Jul 6, 2022

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Chimeric Therapeutics Limited (ASX: CHM)
ABN:	68 638 835 828

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Dr George Matcham
Date of Last Notice:	30 March 2022

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Direct or Indirect Interest	Indirect
Nature of indirect interest	Held via broker nominee account.
(including registered holder)
Note: Provide details of the circumstances giving rise to the
relevant interest.
Date of change	4		July 2022
No. of securities held prior to change				Shares		Options
			Direct	-		2,750,000
			Indirect	658,730		158,730
			Total	658,730		2,908,730
Class			Fully Paid Ordinary Shares
Number acquired				Shares		Options
			Direct	-		-
			Indirect	342,070		-
			Total	342,070		-

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Number disposed				Options---
			Shares	Options
		Direct	-	-
		Indirect	-	-
		Total	-	-
Value/ConsiderationNote:If consideration is non-cash, provide details and estimatedvaluation		$0.098 per share (average)
No. of securities held after change				Options2,750,000158,7302,908,730
			Shares	Options
		Direct	-	2,750,000
		Indirect	1,000,800	158,730
		Total	1,000,800	2,908,730
Nature of changeExample:on-market trade, off-market trade, exercise of options, issueof securities under dividend reinvestment plan, participationin buy-back		On-market Trade

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

irector” should be disclosed in this part.
Detail of contract	N/A
Nature of interest	N/A
Name of registered holder(if issued securities)	N/A
Date of change	N/A
No. and class of securities to whichinterest related prior to changeNote: Details are only required for a contract inrelation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/ConsiderationNote: If consideration is non-cash, providedetails and an estimated valuation	N/A
Interest after change	N/A

Part 3 – Closed period

art 3 – Closed period
Were the interests in the securities orcontractsdetailedabovetradedduring a +closed period where priorwritten clearance was required?	No
If so, was prior written clearanceprovided to allow the trade to proceedduring this period?	N/A

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011

Appendix 3Y Change of Director’s Interest Notice

If prior written clearance was N/A provided, on what date was this provided?

==> picture [38 x 24] intentionally omitted <==

The CFO Solution

• See chapter 19 for defined terms.

01/01/2011

Appendix 3Y Page 3